A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.

AGC Biologics will help the company develop and manufacture RDP-101 in line with FDA standards and for the commercial market.

The payment was triggered because Kura dosed the first AML patient in a Phase III trial of the menin inhibitor.

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one-tenth the standard dose.